Adrecizumab (HAM8101) to Improve Prognosis and Outcomes in COVID-19 Trial

NCT05156671 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

16

Enrollment

OTHER

Sponsor class

Stopped Due to poor recruitment.

Conditions

COVID-19

Interventions

BIOLOGICAL: Adrecizumab (HAM 8101)
DRUG: Placebo

Sponsor

Universitätsklinikum Hamburg-Eppendorf